...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The neurologist. >Phospholipase A2 and Ischemic Stroke Etiology
【24h】

Phospholipase A2 and Ischemic Stroke Etiology

机译：磷脂酶A2和缺血性卒中病因

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Supplemental Digital Content is available in the text. Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2), which is involved in the inflammatory atherosclerotic process, has emerged as an independent risk factor for atheromatous vascular events. Its impact on coronary disease has already been demonstrated, however, its influence in cerebrovascular etiology is still unknown. We aimed to observe and describe the potential association between Lp-PLA2 levels and the etiologic subtype of ischemic stroke. Methods: Unicentric, observational, and prospective cohort study of consecutive patients with acute ischemic stroke, admitted in a comprehensive stroke center. Patients with incomplete investigation or coexisting causes were excluded. Lp-PLA2 was dosed in peripheral blood between day 3 and 14 postevent with “Lp-PLA2-SNIBE” kit. Statistical significance was set for P <0.05. Results: A total of 96 patients were enrolled, with mean age of 75.31±11.88 years, 41 males (42.7%); 12.5% with lacunar stroke, 16.7% atherothrombotic, 46.9% cardioembolic, and 24% embolic stroke of undetermined source (ESUS). The level of Lp-PLA2 was different between etiologies ( F =2.982, P =0.035), being lower in ESUS (143.3±42.8?ng/mL). There were no significant associations with previous vascular risk factors, history of ischemic stroke and modified-Rankin scale (mRS) score 3 months postevent. In ESUS patients, Lp-PLA2 was not associated with cervical ultrasound findings or frequent supraventricular extrasystoles. Conclusions: Lp-PLA2 levels are different between etiologic subtypes of ischemic stroke, being lower in ESUS patients. The results of this study reinforce the existence of distinct pathophysiological mechanisms in patients with ESUS. Multicenter clinical trials with larger sample sizes are needed to clarify the role Lp-PLA2 on the etiology of stroke.
机译：文本中提供了补充数字内容。背景：脂蛋白相关磷脂酶A2（Lp-PLA2）参与炎症性动脉粥样硬化过程，已成为动脉粥样硬化血管事件的独立危险因素。它对冠状动脉疾病的影响已经被证实，然而，它对脑血管病因学的影响仍然未知。我们的目的是观察和描述Lp-PLA2水平与缺血性中风病因亚型之间的潜在关联。方法：对综合性卒中中心收治的连续急性缺血性卒中患者进行单中心、观察性和前瞻性队列研究。排除调查不完整或原因并存的患者。使用“Lp-PLA2-SNIBE”试剂盒，在事件发生后第3天至第14天期间在外周血中给药Lp-PLA2。统计学显著性设定为P<0.05。结果：96例患者，平均年龄75.31±11.88岁，男性41例（42.7%）；腔隙性卒中占12.5%，动脉粥样硬化性血栓占16.7%，心肌栓塞占46.9%，来源不明的栓塞性卒中占24%。不同病因的Lp-PLA2水平不同（F=2.982，P=0.035），ESUS患者的Lp-PLA2水平较低（143.3±42.8纳克/毫升）。与既往血管危险因素、缺血性卒中史和事件后3个月的改良Rankin量表（mRS）评分无显著相关性。在ESUS患者中，Lp-PLA2与颈部超声检查结果或频繁的室上性早搏无关。结论：不同病因亚型缺血性卒中患者的Lp-PLA2水平不同，ESUS患者的Lp-PLA2水平较低。这项研究的结果证实了ESUS患者存在不同的病理生理机制。需要更大样本量的多中心临床试验来阐明Lp-PLA2在中风病因学中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号